- Molecular NameCaptopril
- SynonymCaptoprilum [INN-Latin]; Captopryl; L-Captopril
- Weight217.289
- Drugbank_IDDB01197
- ACS_NO62571-86-2
- Show 3D model
- LogP (experiment)0.546
- LogP (predicted, AB/LogP v2.0)0.67
- pka3.7, 9.8
- LogD (pH=7, predicted)-2.92
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)0.66
- LogSw (predicted, AB/LogsW2.0)35.73
- Sw (mg/ml) (predicted, ACD/Labs)12.42
- No.of HBond Donors1
- No.of HBond Acceptors4
- No.of Rotatable Bonds3
- TPSA96.41
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn angiotensin-converting enzyme inhibitor (ACE inhibitor) used for the treatment of hypertension and some types of congestive heart failure.
- Absorption_value84.0
- Absorption (description)Readily absorbed after oral administration; about 60 to 75% of the dose is absorbed and peak plasma concentrations are achieved within about an hour.
- Caco_2N/A
- Bioavailability62.0
- Protein binding30.0
- Volume of distribution (VD)0.7 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- Metabollsmhepatic
- Half life1.9 h
- Excretion40 to 50% of an oral dose is excreted in the urine as unchanged drug, about 3% as captopril disulfide and about 30% as polar metabolites. Excretion in the urine is rapid, about half the dose being excreted within the first 4 h. An S-methyl metabolite has been identified in plasma and urine. Captopril is removed by haemodialysis.
- Urinary ExcretionN/A
- CleranceBlood clearance, about 13 mL/min/kg.
- ToxicitySymptoms of overdose include coma, lethargy, low blood pressure, sluggishness, and stomach and intestinal irritation and hyperactivity.
- LD50 (rat)N/A
- LD50 (mouse)N/A